Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111941 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT02111941: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT02111941 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02111941, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-04-14 |
| Est. Completion | 2021-07-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02111941
The ClinicalTrials.gov registry entry for NCT02111941 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02111941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02111941 about?
NCT02111941 is a clinical study titled "Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer". This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may h...
What is the current status of trial NCT02111941?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2014-04-14. Estimated completion is 2021-07-27.
What interventions are being tested in trial NCT02111941?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02111941?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.